Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 12Terminated 6Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 112Myeloid 29Lymphoid 16Classical hematology 3Sarcoma 2Plasma cell 2Head & Neck 2Breast 2Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Pathologic Complete Response 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 181pembrolizumab 156Pemetrexed 129Cisplatin 97Drug Therapy 67Paclitaxel 59osimertinib 56Magnetic Resonance Spectroscopy 50durvalumab 49Specimen Handling 49Radiotherapy 49Nivolumab 49atezolizumab 43Docetaxel 43Etoposide 40Bevacizumab 39Blood Specimen Collection 33tislelizumab 31Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 27Immunotherapy 25Immune Checkpoint Inhibitors 25cemiplimab 23Injections 23aflutinib 20Cetuximab 18Biopsy 18Standard of Care 17Platinum Compounds 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Azacitidine × Thoracic × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡